Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/cancers10060204 http://scihub22266oqcxt.onion/10.3390/cancers10060204 C6025119!6025119!29914088     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancers+(Basel) 2018 ; 10 (6): ä Nephropedia Template TP {{tp|p=29914088|t=2018. The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma |pdf=|usr=}}{{29914088}} gab.com Text The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma JO: Cancers (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=29914088 #FOAvip Hodgkin Lymphoma (HL) is a unique disease entity both in its pathology and the young patient population that it primarily affects. Although cure rates are high, survivorship can be linked with significant long-term morbidity associated with both chemotherapy and radiotherapy. The most significant recent advances have been with the use of the anti-CD30-drug conjugated antibody brentuximab vedotin (BV) and inhibitors of program death 1 (PD-1). HL is genetically wired to up-regulate program death ligand 1 (PD-L1) in >95% of cases, creating a state of so-called ?T cell exhaustion?, which can be reversed with immune checkpoint-inhibitor blockade. The overall and complete response rates to PD-1 inhibitors in patients with relapsed or refractory HL are 70% and 20%, respectively, with a long median duration of response of ~16 months. In fact, PD-1 inhibitors can benefit a wide spectrum of relapsed HL patients, including some who have ?progressive disease? by strict response criteria. We review the biology of HL, with a focus on the immune micro-environment and mechanisms of immune evasion. We also provide the rationale supporting the use of PD-1 inhibitors in HL and highlight some of the challenges of monitoring disease response in patients treated with this immunotherapy. Twit Text FOAVip The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma ????Cancers (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=29914088 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29914088 #FOAvip English Wikipedia <ref>{{Cite pmid|29914088}}</ref> The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma #MMPMID29914088 Meti N; Esfahani K; Johnson NA Cancers (Basel) 2018[Jun]; 10 (6): ä PMID29914088show ga Hodgkin Lymphoma (HL) is a unique disease entity both in its pathology and the young patient population that it primarily affects. Although cure rates are high, survivorship can be linked with significant long-term morbidity associated with both chemotherapy and radiotherapy. The most significant recent advances have been with the use of the anti-CD30-drug conjugated antibody brentuximab vedotin (BV) and inhibitors of program death 1 (PD-1). HL is genetically wired to up-regulate program death ligand 1 (PD-L1) in >95% of cases, creating a state of so-called ?T cell exhaustion?, which can be reversed with immune checkpoint-inhibitor blockade. The overall and complete response rates to PD-1 inhibitors in patients with relapsed or refractory HL are 70% and 20%, respectively, with a long median duration of response of ~16 months. In fact, PD-1 inhibitors can benefit a wide spectrum of relapsed HL patients, including some who have ?progressive disease? by strict response criteria. We review the biology of HL, with a focus on the immune micro-environment and mechanisms of immune evasion. We also provide the rationale supporting the use of PD-1 inhibitors in HL and highlight some of the challenges of monitoring disease response in patients treated with this immunotherapy. äThe Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma(epmc).pdf DeepDyve Pubget Overpricing